Rieckmann P, Toyka K V
Klinische Forschungsgruppe für Multiple Sklerose und Neuroimmunologie, Neurologische Universitätsklinik, Würzburg, Deutschland.
Eur Neurol. 1999;42(3):121-7. doi: 10.1159/000008084.
The promising results of several multicenter studies during the last few years have improved the immunomodulatory treatment of multiple sclerosis (MS). The different compounds tested were shown to reduce the number of relapses and to modulate the course of disease to various extents. The transition of the results obtained in therapeutic trials into daily clinical practice is often delayed or even hampered by monetary restrictions or reluctance of the medical community to adjust their approach to new treatments. After an initial inquiry had shown that less than 50% of eligible patients received any active immunomodulating treatment, a consensus group of Austrian, German and Swiss MS societies was formed in order to prepare a report of the current treatment options in MS. The aim of this report is to present the consensus on a new concept of escalating immunotherapy in MS. Future updates of the report are planned on a yearly basis or whenever substantial new evidence becomes available.
过去几年里，多项多中心研究取得的喜人成果改善了多发性硬化症（MS）的免疫调节治疗。所测试的不同化合物均显示出能减少复发次数，并在不同程度上调节疾病进程。治疗试验所获结果向日常临床实践的转化常常因资金限制或医学界不愿调整其对新疗法的应用方式而延迟，甚至受阻。初步调查显示，不到50%的符合条件的患者接受了任何有效的免疫调节治疗后，奥地利、德国和瑞士的MS协会组成了一个共识小组，以编写一份关于MS当前治疗选择的报告。本报告的目的是就MS中逐步升级免疫治疗的新概念达成共识。计划每年或有大量新证据时对本报告进行更新。
